PDCD1 and cancer: This finding corresponds well to the specific lack of proliferative response to SADR-2 stimulation in CD8+ T cells (Fig. 4b) as well as the correlation between increased CD8+ T-cell activation and response to anti-PD-1 therapy in patients with cancer and chronic virus infections (15, 22).